In May 2018 the World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products). From clinical translation to commercialisation this congress will bring you the most exciting case studies and new data for stem cells, gene therapy, TCRs and gene editing. Experts in every area will help you tackle the process and regulatory hurdles of developing all new therapeutic formats all the way through manufacture and into the clinic.
The event will take place alongside the co-located World Precision Medicine Congress and Cord Blood World Europe, hosting 200+ speakers, 7 tracks of content across the 3 days, enabling networking opportunities with 800+ leading industry professionals.
Key topics include:
The next generation of ATMPs
Regulation, reimbursement & commercialisation for advanced therapies around the globe
CRISPR & gene editing
Stem cells as a tool for drug discovery
What’s next for cell and gene therapy, new era of regenerative medicine?
New paradigms in manufacture: gene therapy & viral vectors
Clinical development of immunotherapy & cell therapy
New frontiers in repair and replacement of diseased tissues & organs
Product, process & manufacturing development of ATMPS
Premium Conference Ticket: GBP 2595
Academic Ticket: GBP 1295
Speakers: Ajan Reginald, Chief Executive Officer, Celixir, - Alain Vertès, Managing Director, NxR Biotechnologies, - Alex Pemberton, Programme Manager UKRMP, Medical Research Council, - André Choulika, Chairman & Chief Executive Officer, Cellectis, - Bob Harman, CEO, VetStem Biopharma, Inc., - Benjamin Shepherd, Director, Therapeutics, Organovo, - Chaim Lebovits, CEO, Brainstorm Cell Therapeutics, - Damien Bates, Chief Medical Officer & Head of Research, SanBio, - David Pettitt, Research Associate, Centre for the Advancement of Sustainable Medical Innovation (CASMI), DPhil Candidate, Medical Sciences, University of Oxford, - Didier Caizergues, Head of Regulatory Affairs Department, Genethon, - Diego Ardigò, Project Lead, Chiesi Group, - Eduardo Bravo, Managing Director and CEO, TiGenix, - Ian Campbell, Director for Health and Life Sciences, Innovate UK, - James Noble, CEO, Adaptimmune, - Jeff Abbey, CEO, Argos Therapeutics, - Jeffrey Schaffer, Director of Veterinary Professional Services, VetStem, - John Tchelingerian, CEO, Promethera, Biosciences, - Margo Roberts, CSO, Kite Pharma, - Mark Zimmerman, Vice President, Business Development and Strategy, ViaCyte, - Mehis Pilv, Cofounder and Managing Director, GeneCode Ltd, - Michael West, Co-CEO, BioTime & CEO of AgeX Therapeutics, - Michele Lipucci, CAT Full Member, Patients’ representative, EMA, - Nick Crabb, Programme Director – Scientific Affairs, NICE, - Ohad Karnieli, Chair, Process and Product Development Subcommittee, ISCT ; CEO & Co-Founder, ATVIO, - Susan Solomon, CEO and Co-Founder, New York Stem Cell Foundation, - Todd McAllister, Executive Director, Amnion Foundation, - Yen Choo, CEO, Progenitor Therapeutics, - Zami Aberman, Chairman & CEO, Pluristem Therapeutics